Table 1.

Overview of Published and Pending Clinical Trials for Psychiatric Disorders

Psychiatric Disorder	Studies & Participants	Dose Range (mg)	Route	Treatment time	Adverse Events	Overall Effects	Registered on Clinicaltrials.gov**
Psychotic Disorders	6 (N=190)*	300–1000	Oral	Acute – 6 wks	Sedation (n=1); Mild GI discomfort, dyslipidemia, nausea (n=1); Not Reported (n=3)	Mixed (3 positive, 3 null***)	13
Anxiety Disorders	3 (N=83)	300–600	Oral	Acute – 4 wks	None (n=2), Not Reported (n=1)	Positive	9
Tobacco Use Disorder	3 (N=54)*	400 800	Inhaled Oral	7 days Acute	None (n=1); Not Reported (n=2)	Mixed (2 positive, 1 null)	0
Cannabis Use Disorder	2 (N=115)	200, 400, 800	Oral	Acute – 4 weeks	GI, headache, anxiety, fatigue, cold symptoms, pain, increased heart rate	Mixed	7
Opioid Use Disorder	1 (N=42)	400, 800	Oral	3 days	None	Positive	7
Alcohol Use Disorder	0	N/A	N/A	N/A	N/A	N/A	5
Stimulant Use Disorder	0	N/A	N/A	N/A	N/A	N/A	0
Insomnia	1 (N=15)	40, 80, 160	Oral	Acute	Not Reported	Mixed	1
PTSD	0	N/A	N/A	N/A	N/A	N/A	4
ASD	0	N/A	N/A	N/A	N/A	N/A	5
ADHD	0	N/A	N/A	N/A	N/A	N/A	0
Mood Disorders	0	N/A	N/A	N/A	N/A	N/A	3
Total	16 trials (N=499)	40–1000 mg	Oral (n=15) Inhaled (n=1)	Acute-6 weeks	Minimal side effects	9 positive, 4 null, 3 mixed	54 registered trials

^*Two publications from the same clinical trial. Subjects included once in total N for psychosis (n = 15; Refs. O’Neill et al., 2020 and O’Neill et al., 2021) and tobacco use disorder (n = 20, Refs. Hindocha et al., 2018a and Hindocha et al., 2018b).

^**As of April 20, 2021. Subject to change.

^***Results from O’Neill et al. (2020) were trending towards positive for change in median total PANSS.